Is Interstitial Lung Disease a Type of Lung Cancer?

Lung interstitial changes are not a type of lung cancer. They refer to a broad category of structural and functional abnormalities affecting the pulmonary interstitium—the delicate network of connective tissue, blood vessels, and lymphatic channels that surrounds the alveoli and supports gas exchange. These changes may manifest radiologically as reticular opacities, ground-glass attenuation, honeycombing, or traction bronchiectasis on high-resolution computed tomography (HRCT).

Interstitial lung abnormalities can arise from numerous non-malignant conditions, including idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis, connective tissue disease–associated interstitial lung disease (e.g., in systemic sclerosis or rheumatoid arthritis), drug-induced lung injury, and chronic environmental exposures such as asbestos or silica. While some interstitial lung diseases—particularly IPF and certain forms of progressive fibrosing ILD—confer an increased risk of developing lung cancer over time, the interstitial changes themselves represent neither malignancy nor a precursor lesion.

It is critical to distinguish between incidental interstitial findings on imaging and primary lung malignancies, which typically appear as solitary or multiple pulmonary nodules, masses, or areas of consolidation with spiculated margins, cavitation, or rapid growth on serial imaging. When interstitial abnormalities coexist with a suspicious nodule or mass, further evaluation—including PET-CT, biopsy, or multidisciplinary review—is warranted to rule out concurrent malignancy or paraneoplastic phenomena.

In clinical practice, accurate characterization of interstitial changes requires integration of imaging features, pulmonary function testing, serologic markers, and, when indicated, histopathologic assessment. Misclassifying interstitial disease as lung cancer—or vice versa—can lead to inappropriate management, delayed diagnosis, or unnecessary invasive procedures.